Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
about
Challenges in assessing transmission of Mycobacterium tuberculosis in long-term-care facilitiesPharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individualsHepatotoxicity from antituberculous therapy in the elderly: a systematic reviewIncidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisAdverse reactions to first-line antituberculosis drugs.Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus.Antituberculous drugs in patients with chronic liver disease.Hepatic safety of antibiotics used in primary careTherapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in miceSevere hepatic complications of antituberculous therapySafety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.Unique aspects of antimicrobial use in older adults.Diagnostic and therapeutic problems of pulmonary tuberculosis in elderly patients.Hepatotoxic effects of therapies for tuberculosis.Drug-induced liver injury in the elderly.[Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health].Tuberculosis prevention and control in long-term-care facilities for older adults.Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment.
P2860
Q24169745-E40EC48D-1E48-4C18-B820-36506E467D19Q24815657-6BB7DABA-0D3B-4493-8641-AC555110E030Q27022370-2F7E9F3E-B146-4E11-B88C-D492AE95F593Q28207601-00CD3A37-188C-4092-87C4-6643F6A9E20AQ34497890-8A149897-BED4-4EE9-9AE9-1D6A8E7F5DB4Q35010245-33BD1704-D8B3-4BD7-B0E0-9DFCC4083CB4Q35020875-38AB33E5-1959-43D9-870C-A76B4C4FDD5CQ35037383-37F4ECA9-A4ED-4ADE-A489-6FC2621F36F2Q35136440-0F21E963-9510-4C57-B98D-7B9B46FC3B18Q35649646-4D752D77-204D-4FC9-B162-5A1904275CA1Q35779318-6C474B70-FBDA-43D0-A78B-D89089226DEBQ36095859-4B0D8091-F140-474C-AE94-36EC94243E2BQ37425685-E23F9720-4E17-4E81-A2ED-452FD609627AQ37784382-146B1772-7150-4903-A6AC-655A10096686Q38068354-697B2DE2-3ECA-4CD2-8720-B0AF22C70C18Q43058967-9694DD5A-AF44-4351-9AAB-528007A318B1Q44157851-FD4EFBA0-3309-47AF-85F9-A2217A439647Q44225838-05E31A4C-136C-428D-A223-9A83C6B69D8FQ55517833-C28E1415-B32D-461E-9626-513556ECBC61
P2860
Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
@en
Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
@nl
type
label
Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
@en
Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
@nl
prefLabel
Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
@en
Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
@nl
P2093
P1476
Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
@en
P2093
G Vervoort
P van den Brande
W van Steenbergen
P304
P356
10.1164/AJRCCM.152.5.7582317
P407
P433
P577
1995-11-01T00:00:00Z